The purpose of this study is to find the highest dose of the investigational drug veliparib that can be given safely with radiation to the chest wall and lymph nodes in patients who have had a mastectomy in the past and are experiencing a recurrence of breast cancer in the chest wall or nearby areas, or in patients with inflammatory breast cancer that has been recently removed by mastectomy. Researchers hope that veliparib may enhance the beneficial effects of radiation therapy.
Veliparib (also known as ABT-888) is known as a PARP inhibitor. It kills cancer cells by blocking the PARP protein, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more vulnerable to anticancer treatments. Veliparib is a pill that is taken orally (by mouth).